Radiation and immunotherapy for advanced bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests combining a targeted radiation treatment (radioembolization) with two immunotherapy drugs (tremelimumab and durvalumab) for people with advanced intrahepatic cholangiocarcinoma that cannot be removed by surgery. It aims to shrink tumors and control cancer spread to lymph nodes or one other organ.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and weigh more than 66 pounds.
- Your bile duct cancer is confirmed by biopsy and is either too advanced for surgery or has spread to only a few spots outside the liver (like up to 3 lymph nodes or a single small tumor in another organ).
- You are able to do your daily activities with minimal help (ECOG score 0 or 1).
- Your liver function is good (Child Pugh A, ALBI grade 1 or 2) and your blood counts and kidney function are within safe limits.
- You have not had more than one prior chemotherapy for this cancer, and no prior radiation beads or cancer vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation therapy (PULSAR), immunotherapy, and chemotherapy for advanced bile duct cancer. It aims to see if this approach can shrink tumors and improve survival.
This trial combines a liver-directed radiation therapy (radioembolization) with a targeted drug to treat a specific type of bile duct cancer that cannot be surgically removed. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of two immunotherapy drugs with chemotherapy for people with advanced bile duct cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial studies whether combining Y-90 liver radiation with an immunotherapy drug (durvalumab) and chemo (gemcitabine and cisplatin) can better control locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help shrink tumors and slow disease growth, depending on how well the treatment works for your cancer type and overall health.
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
This study tests a treatment for intrahepatic cholangiocarcinoma (a type of liver cancer) that can be surgically removed. It combines the usual chemotherapy drugs (cisplatin and gemcitabine) with the immunotherapy drug durvalumab, and compares it to the same regimen plus a targeted therapy called futibatinib, which works on specific genetic changes in the tumor. The goal is to see if adding the targeted therapy helps shrink the tumor before surgery and improves the outcome.
Hear when a new Locally Advanced Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.